PDCD1 and melanoma: Since the advent of immunotherapy, unprecedented successes have been achieved in melanoma therapy by application of anti-programmed cell death protein 1 (PD-1) antibodies (pembrolizumab and nivolumab) and anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibodies (ipilimumab).